GLP-1 receptor agonists × glycemic control

SynthesisDiabetes, obesity & metabolism2017

A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.

Mirna S Abd El Aziz et al.PubMed ↗Publisher ↗

  • GLP-1 RAslooks good hereLower long-term blood sugar, no range given.No ranges given.
  • Basal insulinlooks good hereLower fasting blood sugar, no range given.No ranges given.

What the trial testedas reported · 2017

No range given

Reported lower long-term blood sugar, no range given

−0.12percentage points

GLP-1 RAs vs insulin

As reported

difference −0.12 %, no interval · the paper's word: HbA1c

No range given

Reported lower fasting blood sugar, no range given

−1.80mmol/L

basal insulin vs GLP-1 RAs

As reported

difference −1.8 mmol/L, no interval · the paper's word: fasting plasma glucose

Who was studied, and how

6,000people in the Effectiveness and Persistence of Therapy With GLP-1 Receptor Agonists in Clinical Practice. A Multicenter Retrospective Study trial, from 2018
of them with hypertension, in this paper

The trial randomly assignedassigned by chance

GLP-1 RAs
insulin

Reported lower long-term blood sugar, no range given−0.12

randomised

The trial randomly assignedassigned by chance

basal insulin
GLP-1 RAs

Reported lower fasting blood sugar, no range given−1.80

randomised

the abstract, start to end

in reducing fasting plasma glucose (Δ -1.8 mmol/L, P < .0001).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
HbA1cGLP-1 RAs vs insulin
−0.12
Fasting plasma glucosebasal insulin vs GLP-1 RAs
−1.8
GLP-1 receptor agonistsInsulinGlycemic control
1 / 4

70 papers cite itlatest 60 shown

2017
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 27717195